Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 4 Study of Development of Pharmacogenomic Method to Predict Antidepressant Responsiveness

NCT00817011 is registered in ClinicalTrials.gov with Samsung Medical Center as lead sponsor.

NCT NCT00817011
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00817011 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 4 Study of Development of Pharmacogenomic Method to Predict Antidepressant Responsiveness
Lead sponsor
Samsung Medical Center
Phase
Not applicable
Overall status
Unknown status
Start date
April 30, 2006
Completion date
March 31, 2018
Enrollment
1,000 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

antidepressant drug adverse reaction, depression